Teva hopes generic EpiPen will sell well in U.S. market

An EpiPen, or epinephrine auto-injector, is a medication used to treat serious allergic reactions in emergencies.

By
March 3, 2019 16:56
1 minute read.
epipen

EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016. . (photo credit: JIM BOURG / REUTERS)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Teva Pharmaceutical Industries Ltd. predicted that by the end of 2019 its generic version of the Mylan EpiPen will conquer a quarter of the US market, Teva CEO Kåre Schultz said on Tuesday, according to the Jewish News Syndicate (JNS).

“When the device’s approval was announced last year, analysts suggested it could add $250 million to Teva’s annual revenue and 4-6 cents per share in earnings, providing a welcome lift for a company that has fired thousands of employees and worked to reduce its debt load to $27 billion from $35 billion,” Reuters reported.

An EpiPen, or epinephrine auto-injector, is a medication used to treat serious allergic reactions in emergencies.

Mylan who has owned the rights since 2007, increasingly raised the price for the product, hiking the product to more than 500% over a decade, according to Business Insider.


After much backlash, Mylan created a generic version of their product that costs some USD $300. While other similar devices exist, none of the them have captured the market like Mylan, which held 50% of the market as of 2018, according to the same report. The US Food and Drug Administration approved Teva's version of the product in August 2018.

Shultz believes that by the end of 2020, Teva could also capture 50% of the market, JNS reported.


Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Yair Maimon
March 19, 2019
Science meets ancient knowledge in cancer care

By GUY TRAIBER